Recently, we cloned the human myo-inositol monophosphatase 2 (IMPA2) cDNA and established its map location to chromosome 18p11.2, a region previously implicated in bipolar disorder. Because the myo-inositol monophosphatase enzyme has been shown to be inhibited by lithium, an effective therapeutic agent for bipolar disorder, IMPA2 is a plausible positional and functional candidate gene. To permit comprehensive screening for variants we characterized the genomic structure and isolated the potential promoter of IMPA2. The gene was found to encode eight exons spanning ෂ27 kb. The proximal 1-kb 5Ј flanking region did not contain an obvious TATA box but multiple potential binding sites for Sp1 and consensus motifs for AP2 and other transcription factors were evident. Sequencing of the coding region and splice junctions in unrelated bipolar disorder patients detected novel variants. A missense mutation in exon 2, His76Tyr, was found in one patient. His76 is evolutionarily conserved and replacement with Tyr introduces a potential site for phosphorylation. The other polymorphisms included an RsaI polymorphism, IVS1-15GϾA, and a T → C silent mutation in the third nucleotide of codon 53 in exon 2. By Fisher's exact test the silent mutation showed a trend for association (P = 0.051) with bipolar disorder suggesting that further scrutiny of this gene is warranted. Molecular Psychiatry (2000) 5, 165-171.
Introduction
Bipolar affective disorder is a severe mental illness with complex genetic characteristics and unknown etiology. Multiple genes that exert weak to moderate effects and undefined environmental factors are believed to contribute to overall susceptibility. Following the report of linkage to bipolar disorder in the broad centromeric region of chromosome 18, 1 genetic analysis with densely-spaced markers on the same pedigree series localized the maximal peak of excess allele sharing in affected-sib-pairs to 18p11.2. 2 Increased allele sharing in this region has been reported also in other independently ascertained pedigrees. 3, 4 Recently, we cloned a novel human IMPA cDNA, IMPA2 (we originally referred to this gene as IMP.18p 5 ) , that showed 54% amino acid identity to human IMPA1, and homology to IMPAs of other organisms. 5 Radiation hybrid mapping localized IMPA2 to
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Received 30 April 1999; revised and accepted 17 September 1999 18p11.2, 5 distinct from the chromosomal location of IMPA1. 5, 6 Since lithium salts are effective in the treatment of bipolar disorder and have been shown to inhibit IMPA activity (reviewed in 7, 8 ), IMPA2 may be a compelling functional and positional candidate gene for bipolar disorder. To facilitate screening of the entire gene for possible disease-related variants, we determined the genomic structure of IMPA2 and isolated its promoter. In addition, we detected novel variants and analyzed them for possible correlation with affective disorder.
Materials and methods
To characterize the exon-intron organization and 5Ј flanking region of IMPA2, cosmid clones were isolated from a chromosome 18-specific cosmid library, LL18NCO2 (Lawrence Berkeley Laboratory, Livermore, CA, USA). High-density filters of the library were prepared and probed with the IMPA2 cDNA to isolate positively hybridizing cosmid clones. Further characterization of cosmids was done by PCR using primers designed from various regions of the IMPA2 cDNA. By this method the location and sequence of the exonintron boundaries were determined. Sequencing was performed on an ABI 373 DNA sequencer by the use of either the dye terminator cycle sequencing kit with
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TaqFS or the dye primer method (Perkin ElmerApplied Biosystems, Foster City, CA, USA). Heterozygotes were resolved by sequencing from opposite directions using the dye primer method. The GC-rich splice site at the exon 1-intron 1 boundary was sequenced manually with the use of the SequiTherm EXCELL Cycle Sequencing kit (Epicentre Technologies, Madison, WI, USA). Long range PCR was done on both cosmid and human genomic DNAs using the Expand Long Template PCR system (Boehringer Mannheim/ Roche Molecular Biochemicals, Indianapolis, IN, USA).
The transcription start site of the gene was determined by primer extension analysis using the Primer Extension System kit (Promega, Madison, WI, USA). An IMPA2-specific antisense oligonucleotide primer referred to as IMPext1 (p in Figure 1b ) was end-labeled in a T4 polynucleotide kinase reaction in the presence of [␥- PRIME, Inc, Boulder, CO, USA), ethanol precipitated, and annealed to ෂ1.6 g skeletal muscle poly(A)+ RNA (Clontech, Palo Alto, CA, USA) overnight at 58°C in a PIPES buffer containing 80% formamide. Ethanol precipitation was performed and the mRNA-primer complex was subjected to reverse transcription with AMV reverse transcriptase at 42°C for 40 min. The extended product was concentrated, loading buffer was added and denaturation was performed at 95°C for 10 min.
Cycle sequencing was conducted using the EXCELLII Sequencing kit (Epicentre Technologies) (Figure 1a ). The sequencing primers were end-labeled in a T4 polynucleotide kinase reaction in the presence of [␥ 33 P]ATP (3000 Ci mmol −1 , ICN Biomedicals Inc). The IMPext1 primer was used in sequencing the appropriate region in cosmid 119C4 and amplimers generated from the 5Ј flanking region of IMPA2 in two unrelated individuals. The upstream primer was tailed with a T7 promoter oligomer on the 5Ј end: TAATACGACTCACTAT AGGGTGGGAGGAGGATGTTTGCATG. The downstream primer was tailed with an M13-derived olig- omer: TGTAAAACGACGGCCAGTCTGCATTCTCTAT GAGTGTGG. Cycle sequencing was performed using either the T7 or M13 primers. Control reactions were done using pUC18 as template and an M13 forward primer. Electrophoresis was performed on a 6% sequencing gel followed by autoradiography at −70°C with an intensifying screen.
Results

Genomic organization of the IMPA2 gene
We have isolated three overlapping cosmid clones 119C4, 97A4 and 69E10, from a chromosome 18 genomic library. These cosmids were found to span the entire coding region of the IMPA2 gene ( Figure 2 ). To determine the location of the exon-intron boundaries a series of PCR amplifications using primers from various regions of the IMPA2 cDNA was performed on cosmid DNA templates followed by direct sequencing of amplimers. This analysis detected eight exons ranging in size from 46 bp to 535 bp ( Figure 2 ). The introns (1-7) had a size range of 600 bp to ෂ12 kb, giving an estimated gene size of ෂ27 kb ( Table 1 ). The splice 
donor and acceptor sites had the canonical dinucleotides GT and AG, respectively.
Transcription start site and promoter
To determine the location of the transcription start site, primer extension analysis was performed in the presence of a primer that included the initiation codon ( Figure 1 ). The major extension product was 337 bp (Figure 1a) . Two additional products of lower intensity were visible, one located upstream and another downstream of the major band suggesting that IMPA2 could utilize one major transcription start site and two alternate minor sites. Analysis of the sequence around the transcription start site failed to reveal TATA and CAAT boxes (Figure 1b) . Exon 1 and the proximal portion of the 5Ј flanking region contained ෂ80% G-C. Multiple potential recognition elements for Sp1 and consensus motifs for other transcription factors such as HNF-5, GCF, and p53 were also found (Figure 1b) .
Screening for IMPA2 variants
To screen for variants in the IMPA2 gene, all eight exons and splice junctions were PCR amplified with primers shown in Table 2 in 22 unrelated bipolar patients taken from a panel of multiply affected pedigrees segregating bipolar disorder. 1,2 The products of amplification were sequenced directly by using the dye primer method. This analysis revealed polymorphisms in exon 2 and in intron 1 flanking this exon (Figures 2  and 3 ). Fifteen bp upstream of the 5Ј splice site of exon 2, a G → A transition was detected in a RsaI recognition site, IVS1-15GϾA. Five of the 22 patients were heterozygous for this position with no homozygotes for the A allele (Figure 3a) .
Another variant was found in the same amplimer. One of 22 patients was a heterozygote, C/T, at the first nucleotide of codon 76 resulting in a His → Tyr amino acid substitution (Figure 3b ). To determine how the His76Tyr mutation is transmitted in the pedigree (No. 0643), this region was analyzed in the other available family members. The majority of the affected individuals had the wild-type C, and the T allele in one sibship originated from an unaffected father marryingin (Figure 4 ). Further sequencing of this region was done in one additional affected person from each of the 22 families to determine if allelic heterogeneity existed but no other heterozygote for the missense mutation was found. Similarly, neither of the two RsaI alleles seemed to correlate with illness in this family.
In this same family a silent mutation was found also in exon 2, a T→C transition in the third nucleotide of codon 53 5 ( Figure 3c ). The segregation of these alleles indicated that it is a single nucleotide polymorphism that did not correspond to disease transmission in this pedigree (Figure 4 ). Sjoholt et al (see accompanying paper) detected the Rsa I variants and the silent mutation also.
To determine the allele frequencies in the three polymorphisms, 59 unrelated individuals from the CEPH families were analyzed. Similarly, 96 unrelated bipolar patients from the NIMH Genetics Initiative bipolar pedigrees 9 were examined. As shown in Table 3 , the polymorphisms were infrequent. The missense mutation was not found in these additional samples. By the Fisher's exact test the allele frequencies of the Rsa I polymorphism were equivalent in the CEPH unscreened controls and bipolar samples ( Table 2 ). The silent mutation showed a trend for association (P = 0.051) ( Table 3) .
Discussion
We have determined the genomic structure of IMPA2 to permit screening of the coding region, splice junctions and 5Ј flanking region of the gene for possible mutational variants in bipolar disorder. IMPA2 is encoded by eight exons with a major and two potential minor transcription start sites. We have shown previously that IMPA2 included two motifs, A (residues 98-111) and B (residues 230-244), that are conserved in animal inositol phosphatases. 5, 10 These motifs are contained in separate exons, A in exon 3 and B in exon 7. Note that the transcription start site found by Sjoholt et al (see accompanying paper) who used brain mRNA is different from that which we found by using skeletal muscle mRNA. The potential promoter is TATA-less, reminiscent of promoters of housekeeping genes, oncogenes, growth factors, growth factor receptors, and transcription factors (reviewed in 11 ). Prominent features shared by these types of promoters include: (a) cap site heterogeneity; (b) a GC-rich sequence with multiple CpG islands; (c) multiple Sp1 consensus motifs. Sp1 elements have been shown to participate in the transcriptional activation of TATA-less genes. [12] [13] [14] We have reported previously that IMPA2 displays a differential pattern of expression in a variety of fetal and adult tissues. 5 Although minimal levels of the transcript are found in whole brain, the gene exhibits a prominent expression in specific brain structures. The abundant expression in skeletal muscle may be due to the presence of an E-box (Figure 1b) , a target of the MyoD family. 15 Other potential regulatory elements include four AP2 recognition sequences within the proximal 1.1-kb region. Prior studies have shown that AP2 may be important in mediating transcriptional activation through protein kinase C and the cAMPdependent protein kinase pathway. 16 The IMPA2 promoter also contains potential binding sites for p53, t-antigen, GCF and HNF-5. A detailed dissection of the promoter would establish the role of these elements in IMPA2 gene regulation.
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The missense mutation in IMPA2 is demonstrable only in one family transmitting bipolar disorder but the majority of affected persons typed, including an obligate carrier, had the wild-type C allele. In addition, in one sibship the mutated allele originated from an unaffected father marrying-in. Although it is unlikely that this mutation contributes to genetic risk, it is important to note that His76 is conserved 5 and substitution with Tyr creates a potential site for phosphorylation. The exact functional consequence of this amino acid change remains to be determined. In the current sample the silent mutation and IVS1-15GϾA polymor-Molecular Psychiatry Fisher's exact test: for silent mutation, P = 0.051; for Rsa I RFLP, P = 0.144.
phism are infrequent with the latter showing equivalent allele frequencies in controls and bipolar disorder patients. The silent mutation seems to be increased in this bipolar disorder sample, however, demonstration of an association would require analysis of a larger sample size. Also, other regions including the regulatory portion of the IMPA2 gene remain to be screened for possible disease-related variants. Interestingly, the region of chromosome 18p11.2 has been proposed to include also a susceptibility locus for schizophrenia. 17 One of the alleles of GNAL (G olf␣ ) was found to be associated with schizophrenia, and the statistical significance increased when affective disorder was included in the affected phenotype category. We found that GNAL and IMPA2 are located in the same BAC clones, indicating that these two genes are within a ෂ100 kb stretch of chromosome 18 DNA (Reyes et al, unpublished data). Linkage disequilibrium spanning a short physical distance on 18p11.2, which includes GNAL and IMPA2, may exist. Therefore, screening of IMPA2 for possible association with schizophrenia would be important. The overlap of susceptibility regions for affective disorder and schizophrenia on 18p11.2 is intriguing as it suggests shared loci for these disorders.
